Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

Maurizia Brunetto; Soo Aleman; Pietro Andreoné; Pavel Bogomolov; Vladimir Chulanov; N Geyvandova; Vitaly Morozov; Olga Sagalova; T. E. Stepanova; Katja Deterding; Andrew H. Lichtman; Renée-Claude Mercier; D Manuilov; Mingyang Li; Julian Schulze zur Wiesch; Stefan Zeuzem; H. Wedemeyer; Pietro Lampertico

doi:10.1055/s-0045-1810984

Key Points

Bulevirtide therapy improves noninvasive test outcomes, enhancing liver disease management.
After 144 weeks, studies indicate significant improvement in test results for patients with chronic hepatitis delta.
Patients receiving bulevirtide therapy showed improved hepatic function and reduced disease burden.
This analysis provides evidence supporting the efficacy of bulevirtide, suggesting benefits even in cases without virologic response.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows improved hepatic function in chronic hepatitis delta patients, indicating effectiveness of bulevirtide therapy for liver disease burden.

Abstract

Introduction: Bulevirtide (BLV) is a therapy for patients (pts) with chronic hepatitis delta (CHD); noninvasive tests (NITs) have shown improvements in hepatic function and liver disease burden with BLV treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brunetto et al. (2025) studied this question.

synapsesocial.com/papers/68c194029b7b07f3a061873b https://doi.org/10.1055/s-0045-1810984

View at Publisher

Ask AI

Bookmark

Share

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading